Mortality in the intervention group was significantly lower than in the standard-of-care group for the three prespecified high-risk subgroups: adjusted risk difference −7·1% (95% CI −13·7 to −0·4) in patients with baseline CD4 counts less than 100 cells per μL, −9·0% (−16·6 to −1·3) in patients with severe anaemia, and −5·7% (−10·9 to −0·5) in patients with clinically suspected tuberculosis at admission (figure 2). The gene discussed is CD4; the disease is anemia.